Friday: The FDA Drops the Hammer On February 6th, one day after the HIMS launch, FDA Commissioner Martin Makary issued a statement that may be the most consequential regulatory action in the compounded GLP-1 saga to date
Drawing up more units than prescribed can increase the risk of nausea, vomiting, or other gastrointestinal symptoms, while drawing fewer units than intended may reduce the treatments effectiveness for the intended condition, whether that is blood sugar management or weight management
GLP-1 Booster is a vague term that can refer to several different mechanisms involved in stimulating GLP-1 production
Like most research peptides, retatrutide is sensitive to heat, light, repeated freeze-thaw cycles, and prolonged exposure at ambient temperatures
Oral semaglutide is a medication used primarily for weight loss in individuals who are not diabetic